6/12 Initiators and active members – Workshop day – Tank Meeting
Together with AstraZeneca we discussed new methods and ways for large and small organizations to collaborate and cooperate.
Find the report from the tank meeting here.
We started with the eight types of Asymmetric Collaboration – Find Prof. Bengt Järrehults full presentation here. And Bengts how to select partners, deepen your engagement with startups and a summary on how to make asymmetric collaborations deliver on innovation here.
After that we used the BioVentureHub in Mölndal as one example of how to do this.
Find CEO Magnus BJörsnes presentation here.
The Bio Hub is AstraZeneca’s contribution to a more dynamic and competitive life science ecosystem in Scandinavia. A new business model of adding value & reducing risks. Our discussion started here and expanded into the participants industries.t the Mölndal site Astra Zeneca opens up their offices, laboratory space and facilities to academic groups and biotech companies that could benefit from AstraZeneca’s corporate R&D infrastructure and R&D competence. How does Astra Zeneca align high calibre academic groups to the AstraZeneca strategy, and biotech companies that could gain competitive advantage by tapping into their expertise.
AstraZenecas BioVentureHub lead by CEO Magnus Björsne is a new business model for the life science industry as it adds value by allowing companies and academic groups within the BioVentureHub to operate at a lower cost base, by utilizing the AstraZeneca capabilities, know-how and infrastructure.
There is a huge value base within pharma and the BioVentureHub introduces novel mechanisms for its utilisation. The BioVentureHub business model enables true win-win constructions for all parties involved: the company/academic group, its investors and AstraZeneca.
